Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment

References

• Salomon D, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Grit. Rev. Oncol Hematol 19(3), 183–123 (1995).
   Google Scholar
• Elenius K, Choi C, Paul S et al Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18(16), 2607–2615 (1999).
   Google Scholar
• Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 31(6), 637–643 (1999).
   Google Scholar
• Woodburn JR, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Them. 82(2-3), 241–250 (1999).
   Google Scholar
• Slamon D, Clark G, Wong S et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235 (4785), 177–182 (1987).
   Google Scholar
• Friess H, Kleeff J, Korc M et al. Molecular aspects of pancreatic cancer and future perspectives. Dig. Surg. 16(4), 281–290 (1999).
   PubMed Web of Science ®Google Scholar
• Porebska I, Harlozinska A, Bojarowski T Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tum. Biol. 21(2), 105–115 (2000).
   Google Scholar
• Grandis J, Melhem M, Gooding W et al. Levels of TGF—a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90(11), 824–832 (1998).
   PubMedGoogle Scholar
• Etienne MC, Formento JL, Lebrun-Frenay C et al Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Gun. Cancer Res. 4(10), 2383–2390 (1998).
   Google Scholar
• Brabender J, Danenberg K, Metzger R et al Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res., 7(7), 1850–1855 (2001).
   Google Scholar
• Yi ES, Harclerode D, Gondo M et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod. Pathol 10(2), 142–148 (1997).
   Google Scholar
• Akimoto T, Hunter N, Buchmiller L et al Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Gun. Cancer Res. 5(10), 2884–2890 (1999).
   Google Scholar
• Dent P, Reardon DB, Park JS et al. Radiation-induced release of transforming growth factor-a activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mal Biol. Cell 10(8) 2493–2506 (1999).
   Web of Science ®Google Scholar
• Fan Z, Shang B, Lu Y et al. Reciprocal changes in p27 (Kipl) and p21(Cipl) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin. Cancer Res. 3(11), 1943–1948 (1997).
   Google Scholar
• Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy — The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 6,747–753 (2000).
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM et al Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59,1935–1940 (1999).
   PubMed Web of Science ®Google Scholar
• Raben D, Helfrich B, Phistry M et al. C225 antiEGFR antibody potentiates radiation (RI) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NscLq cells in vitro and in vivo. ASTRO San Francisco, CA, USA, (2001).
   Google Scholar
• Gorski D, Beckett M, Jaskowiak N et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res, 59(14), 3374–3378 (1999).
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N et al lardy° enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6(2), 701–708 (2000).
   Google Scholar
• Huang SM, Harari P Modulation of radiation response after epidermal growth factor receptor blockage in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin. Cancer Res. 6(6), 2166–2174 (2000).
   PubMed Web of Science ®Google Scholar
• Tortora G, Damian° V, Bianco C et al The RIasubunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 14(8), 923–928 (1997).
   Google Scholar
• Bianco C, Bianco R, Tortora G et al Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus Type I protein kinase A antisense oligonucleotide. Gun. Cancer Res. 6 (11), 4343–4350 (2000).
   Google Scholar
• Lynch DH, Yang XD et al Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol 29(1 Suppl. 4), 47–50 (2002).
   Google Scholar
• Sampson J, Crotty L, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl Acad. Li. USA 97(13), 7503–7508 (2000).
   Google Scholar
• Wikstrand C, Reist C, Archer G et al The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J. Neurovirol. 4(2), 148–158 (1998).
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Ji XD, Harmon RC et al A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Nall Acad. Sci. USA 91(16), 7727–7731 (1994).
   Google Scholar
• Tang C, Gong X. Moscatello D et al Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res: 60(11), 3081–3087 (2000).
   PubMed Web of Science ®Google Scholar
• Luwor R, Johns T, Murone C et al Monoclonal antibody 806 inhibits the growth of tumor xenographs expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild type EGFR. Cancer Res. 61(14), 5355–5361 (2001).
   Google Scholar
• Mishima K, Johns T, Luwor R et al Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61(14), 5349–5354 (2001).
   Google Scholar
• Kris M, Azzoli CG. Chemotherapy for early stage non-small cell lung cancer. Lung Cancer. 34 (Suppl. 3), S49-52 (2001).
   Google Scholar
• Tamura T, Nakagawa K, Fukuoka MA et al. Phase I intermittent dose-escalation trial of ZD1839 (IressaTM) in Japanese patients with solid malignant tumors. Lung Cancer 29(1), (2000).
   Google Scholar
• Laurie SA, Miller VA, Johnson D et al Pilot trial of ZD1839 (Iressa), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Lung Cancer 29(1), (2000).
   Google Scholar
• Baselga J, Herbst R, LoRusso P et al. Continuous administration of ZD1839 (Iressa), a novel oral EGFR tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Doc. Ann. Meet. Am Soc. Clin. Oncol New Orleans, LA, USA, May (2001) (Abstract 686).
   Google Scholar
• Baselga J, Yano S, Giaccone G et al Initial results from a Phase II trial of ZD1839 (Iressa) as secondand third-line monotherapy for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. 12th AACR-NCI-EORTC Meeting on Molecular Targets and Cancer Therapeutics (2001) (Abstract).
   Google Scholar
• Wakeling AE, Barker AJ, Davies DH. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat. 38(1), 67–73 (1996).
   Google Scholar
• Levitt M, Koty P Tyrosine kinase inhibitors in preclinical development. Invest. New DITIF 17(3), 213–226 (1999).
   PubMedGoogle Scholar
• Bridges A, Cody D, Zhou H et al Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(a-phenethylamino) quinazolines. Bioorg Med. Chem. 3(12), 1651–1656 (1995).
   Google Scholar
• Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267(5205), 1782–1788 (1995).
   PubMed Web of Science ®Google Scholar
• Klohs W Fry D, Kraker A. Inhibitors of tyrosine kinase. CUM Opin. Dna. 9(6), 562–568 (1997).
   Google Scholar
• Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82(2-3), 231–239 (1999).
   PubMed Web of Science ®Google Scholar
• Traxler P, Furet P Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther. 82(2-3), 195–206 (1999).
   Google Scholar
• Lichtner R, Menrad A, Sommer A et al Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 61(15), 5790–5795 (2001).
   Google Scholar
• Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6(5), 2053–2063 (2000).
   Google Scholar
• Woodburn JR, Barker AJ, Gibson KH et al ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Cancer Res. 38,633-634 (1997).
   Google Scholar
• Sirotnak F, Zakowski M, Miller V et al Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6(12), 4885–4892 (2000).
   Google Scholar
• Raben D, Helfrich B, Chan D et al The effects of ZD1839 on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitm. Proc of the 12th AACR-NCI-EORTC Intern. Con. Mol Targets Cancer Them. Miami, FL, USA October (2001) (Abstract).
   Google Scholar
• Budillion A, Di Gennaro E, Burzzese F et al. Synergistic antitumor activity of IFN-a in combination with ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, in HNSCC and melanoma lines. Proc of the 11th NCI-EORTC-AACR Sympos. New Drugs Cancer Ther. Amsterdam, The Netherlands, (2000) (Abstract).
   Google Scholar
• Moulder SL, Yakes M, Bianco R et al. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ nue (erb-2) overexpressing breast tumor cells. Proc of the 37th Annual Meeting of the Am Soc Clin Oncol, San Francisco, CA, USA, (2001) (Abstract 5).
   Google Scholar
• Anido J, Albanell J, Rojo F et al Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells. Abstract. Proc. 37th Ann. Meet. Am Soc. Clin. Oncol, San Francisco, CA, USA, (2001) (Abstract 1712) .
   Google Scholar
• Nicholsen RI, Harper ME, Hutcheson IR et al. ZD1839 (Iressa) improves the antitumor activity of Tamoxifen (Novaldex) in antihormone-responsive breast cancer cells. Proc. AACR-NCI-EORTC meeting on Molecular Targets and Cancer Therapeutics. Miami, FL, USA, (2001) (Abstract 557).
   Google Scholar
• Moasser M, Basso A, Averbuch S et al. The tyrosine kinase inhibitor ZD1839 (Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61(19), 7184–7188 (2001).
   Google Scholar
• Haung SM, Harari P Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas. Proc AACR-NCI-EORTC meeting on Ma Targ. Cancer Them. Miami, FL, USA, (2001) (Abstract 259).
   Google Scholar
• Bianco R, Bianco C, Caputo R et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) by ZD1839 (Iressa) potentiates the antitumor effects of ionizing radiation. Proc. Ann. Meet. Am Assoc Cancer Res, San Francisco, CA, USA, (2002) (Abstract 4972).
   Google Scholar
• Williams KJ, Telfer BA, Stratford IJ et al An evaluation of the EGFR-TKI inhibitor, ZD1839 (Iressa) in combination with ionizing radiation. Proc of the 11th AACR-NCI-EORTC Meeting on New Drugs in Cancer Therapy Amsterdam, The Netherlands, (2000) (Abstract L3).
   Google Scholar
• Robert F, Ezekiel M, Spencer S et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.' Clin. Oncol 19(13), 3234–3243 (2001).
   Google Scholar
• Miller VA, Johnson D, Heelan RT et al A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor inhibitor (EGFR-TKI), in combination with carboplatin© and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). PrOC ATI7 Soc Clin Oncol, 20,326a, (2001) (Abstract 1301).
   Google Scholar
• Viloria-Petit A., Crombet T, Jothy S et al Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61(13), 5090–5101 (2001).
   Google Scholar
• Chakravarti A, Loeffler J, Dyson N. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinsitide 3-kinase signaling. Cancer Res. 62(1), 200–207 (2002).
   Google Scholar
• Albanell J, Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. Natl Cancer Inst. 93(24), 1830–1832 (2001).
   Google Scholar
• Tortora G, Caputo R, Damiano V et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A and the epidermal growth factor receptor inhibitor Iressa causes co-operative antitumor and anti-angiogenic activity. Clin. Cancer Res. 7(12), 4156–4163 (2001).
   PubMedGoogle Scholar
• Baselga J, Tripathy D, Mendelsohn J et al Phase II study of weekly iv. recombinant humanized antip185 HERR2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Clin. Oncol. 14m7373-7374 (1996).
   Google Scholar
• Ranson M, Hammond L, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well-tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. Clin. Oncol. 20(9), 2240–2250 (2002).
   Google Scholar
• Saleh M, Saleh MN, Raisch KP, Stackhouse MA et al Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Blather. Racliopharm. 14,451-463 (1999).
   Google Scholar
• Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor (EGFR) signaling. Semin. Racliat. Oncol. 11(4), 281–289 (2001).
   Google Scholar